U.S. markets closed

Metacrine, Inc. (MTCR)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.4071+0.0020 (+0.49%)
At close: 03:57PM EST
0.4070 -0.00 (-0.02%)
After hours: 07:04PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close0.4051
Bid0.4071 x 3100
Ask0.4080 x 4000
Day's Range0.4000 - 0.4100
52 Week Range0.3030 - 1.7300
Avg. Volume495,214
Market Cap17.33M
Beta (5Y Monthly)-0.87
PE Ratio (TTM)N/A
EPS (TTM)-1.9320
Earnings DateNov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for MTCR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Metacrine, Inc.
    Daily – Vickers Top Buyers & Sellers for 12/31/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    11 months agoArgus Research
View more
  • GlobeNewswire

    Metacrine Reports Third-Quarter 2022 Results

    SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company developing differentiated therapies for patients with gastrointestinal diseases, today reported its third-quarter 2022 financial results. “We made great progress during the quarter in advancing our proposed merger with Equillium,” said Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine. “We believe that Equillium has demonstrated compelling clinical d

  • Benzinga

    Equillium Buys Inflammatory Bowel Disease Player In All-Stock Deal

    Equillium Inc (NASDAQ: EQ) has agreed to acquire Metacrine Inc (NASDAQ: MTCR) in an all-stock transaction. The transaction is anticipated to add $33 million in cash to Equillium's balance sheet at closing, which is expected to extend the company's cash runway into 2024. Earlier this year, Metacrine axed 50% of its workforce. Through the acquisition, Equillium adds Metacrine's farnesoid X receptor platform, including lead molecule MET642 for inflammatory bowel diseases. Equillium will be seeking

  • Business Wire

    Equillium to Acquire Metacrine in All-Stock Transaction

    LA JOLLA, Calif., September 06, 2022--Equillium, Inc. (Nasdaq: EQ) and Metacrine Inc. (Nasdaq: MTCR), today announced that the two companies have entered into a definitive merger agreement pursuant to which Equillium will acquire Metacrine in an all-stock transaction. The transaction is anticipated to add $33 million in cash to Equillium’s balance sheet at closing, which is expected to extend the company’s cash runway into 2024. The transaction has been approved by the boards of directors of bot